Posted by Michael Wonder on 09 Oct 2021
Egetis Therapeutics receives FDA fast track designation for Emcitate for MCT8 deficiency
8 October 2021 - Egetis Therapeutics today announced that the U.S. FDA has granted the company’s lead candidate drug Emcitate, currently in a pivotal study, fast track designation for the treatment of the rare genetic disease MCT8 deficiency.
Emcitate was also granted US rare paediatric disease designation in November 2020, eligible to apply for a priority review voucher.
